Compare TPR & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPR | EXAS |
|---|---|---|
| Founded | 1941 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1B | 11.0B |
| IPO Year | 2000 | N/A |
| Metric | TPR | EXAS |
|---|---|---|
| Price | $123.03 | $101.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 20 |
| Target Price | ★ $120.76 | $77.94 |
| AVG Volume (30 Days) | 3.2M | ★ 10.8M |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $7,207,800,000.00 | $3,082,033,000.00 |
| Revenue This Year | $5.95 | $19.40 |
| Revenue Next Year | $4.67 | $13.51 |
| P/E Ratio | $98.50 | ★ N/A |
| Revenue Growth | 8.14 | ★ 14.47 |
| 52 Week Low | $58.39 | $38.81 |
| 52 Week High | $125.18 | $101.95 |
| Indicator | TPR | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 68.78 | 89.13 |
| Support Level | $114.39 | $101.30 |
| Resistance Level | $125.73 | $101.95 |
| Average True Range (ATR) | 3.61 | 0.38 |
| MACD | 1.44 | -1.12 |
| Stochastic Oscillator | 85.06 | 72.00 |
Based in New York City, Tapestry is the parent company of accessories and fashion brand Coach, which accounted for 80% of its revenue and well over 90% of its operating profit in fiscal 2025. Handbags accounted for 58% of the brand's fiscal 2025 revenue. Coach products are sold through more than 900 company-owned stores, e-commerce, and third-party stores in North America, Asia, and Europe. Tapestry also owns Kate Spade (17% of fiscal 2025 revenue), which operates about 170 stores and generated 52% of its sales from handbags in fiscal 2025. Kate Spade is known for its colorful patterns and graphics. Tapestry sold its smallest brand, luxury footwear maker Stuart Weitzman, to Caleres in August 2025.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.